Fast Company Names Veracyte CEO, Bonnie Anderson, to Its "100 Most Creative People in Business 2015" List

SOUTH SAN FRANCISCO, Calif., May 11, 2015 /PRNewswire/ -- Veracyte, Inc. (NASDAQ: VCYT), a molecular diagnostic company pioneering the field of molecular cytology, announced that company President and CEO Bonnie H. Anderson has been selected to Fast Company's "100 Most Creative People in Business 2015" list. This annual program, featured online and scheduled to appear in the magazine's June issue, recognizes men and women across industries and around the globe whose creativity is moving business in new directions.

As a 2015 honoree, Ms. Anderson joins the ranks of Fast Company's Most Creative People 1000 — a community of the world's most innovative and intriguing individuals selected by the publication's editors. According to the magazine, Ms. Anderson was selected "for saving thousands of patients from the knife," referring to the company's first genomic test offering – Afirma® – which helps reduce unnecessary surgeries in thyroid cancer diagnosis.

"Bonnie Anderson is an inspiring and enthusiastic team builder and leader who makes a tremendous addition to this prestigious list," said Brian Atwood, Versant Ventures managing director and Veracyte board chair. "She co-founded Veracyte to help solve a far-reaching healthcare challenge, and her consistently high-caliber thinking and problem-solving have resulted in a successful public company with two marketed products that are positively impacting patients and our healthcare system."

Ms. Anderson co-founded Veracyte in 2008, took the company public in 2013 and has spearheaded the company's commercialization successes to date. These include the introduction of its first product – the Afirma Thyroid FNA Analysis – which is becoming a new standard of care in thyroid cancer diagnosis by helping patients with thyroid nodules avoid unnecessary surgery and by reducing healthcare costs. In April 2015, Veracyte launched its second product – the Percepta™ Bronchial Genomic Classifier – to help reduce unnecessary invasive procedures in lung cancer diagnosis.

Ms. Anderson is a previous recipient of the Silicon Valley Business Journal's "Women of Influence" award (2013), and was named one of the "Most Influential Women in Bay Area Business" (2013) and one of the "Bay Area's Most Admired CEOs" (2014) by the San Francisco Business Times.

About Veracyte
Veracyte (NASDAQ: VCYT) is pioneering the field of molecular cytology, focusing on genomic solutions that resolve diagnostic ambiguity and enable physicians to make more informed treatment decisions at an early stage in patient care. By improving preoperative diagnostic accuracy, the company aims to help patients avoid unnecessary invasive procedures while reducing healthcare costs. Veracyte's first commercial solution, the Afirma Thyroid FNA Analysis, centers on the proprietary Afirma Gene Expression Classifier (GEC) to resolve ambiguity in diagnosis and is becoming a new standard of care in thyroid nodule assessment. Since launching its Afirma solution in 2011, Veracyte estimates it has helped approximately 15,000 patients with thyroid nodules avoid unnecessary surgery, reducing healthcare costs by millions of dollars. The Afirma test is recommended in leading practice guidelines and is covered for 145 million lives in the United States, including through Medicare and many commercial insurance plans. Veracyte intends to expand its molecular cytology franchise to other clinical areas, beginning with difficult-to-diagnose lung diseases. In April 2015, the company launched the Percepta Bronchial Genomic Classifier, a test to resolve preoperative ambiguity in lung nodules that are suspicious for cancer. Veracyte is also developing a second product in pulmonology, targeting interstitial lung diseases, including idiopathic pulmonary fibrosis. For more information, please visit www.veracyte.com.

Veracyte, Afirma, Percepta, the Veracyte logo, and the Afirma logo are trademarks or registered trademarks of Veracyte, Inc.

Media:
Tracy Morris
650-380-4413
[email protected]

Investors:
Pam Lord
Canale Communications
619-849-6003
[email protected]

SOURCE Veracyte

Related Links

http://www.veracyte.com